Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome

We report 2 cases of apixaban use as prophylaxis against thromboembolism in the nephrotic syndrome (NS), and review the existing literature on direct-acting oral anticoagulant (DOAC) use in this scenario. Our cases appear to be the first reported use of apixaban as prophylaxis against thromboembolis...

Descripción completa

Detalles Bibliográficos
Autores principales: Sexton, Donal J., de Freitas, Declan G., Little, Mark A., McHugh, Tomas, Magee, Colm, Conlon, Peter J., O’Seaghdha, Conall M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035159/
https://www.ncbi.nlm.nih.gov/pubmed/29989039
http://dx.doi.org/10.1016/j.ekir.2018.02.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035159/
https://www.ncbi.nlm.nih.gov/pubmed/29989039
http://dx.doi.org/10.1016/j.ekir.2018.02.010

Ejemplares similares